Published in Eur J Pharmacol on April 29, 1986
Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science (2013) 1.91
In vivo activation of a mutant mu-opioid receptor by antagonist: future direction for opiate pain treatment paradigm that lacks undesirable side effects. Proc Natl Acad Sci U S A (2003) 0.89
Long-term sensitization to the activation of cerebral delta-opioid receptors by the deltorphin Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 in rats exposed to morphine. Proc Natl Acad Sci U S A (1992) 0.83
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton. ACS Med Chem Lett (2014) 0.75
Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther (1991) 2.96
International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev (1996) 2.43
Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci (1987) 2.19
Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol (1988) 2.18
Cannabinoid pharmacology. Pharmacol Rev (1986) 2.15
The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. J Pharmacol Exp Ther (1970) 2.01
A survey of the teaching of pain control at the predoctoral level. Anesth Prog (1976) 1.93
In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther (1996) 1.85
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem (1980) 1.80
Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther (1988) 1.73
Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J Pharmacol Exp Ther (1979) 1.69
Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J Med Chem (1990) 1.68
Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS (1990) 1.61
Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther (1997) 1.52
Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice. J Pharmacol Exp Ther (1975) 1.52
Differential effects on morphine analgesia and naloxone antagonism by biogenic amine modifiers. Life Sci (1975) 1.45
Beta-endorphin in cerebrospinal fluid and serum after severe head injury. Neurosurgery (1990) 1.42
Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol (2009) 1.38
Bimorphinans as highly selective, potent kappa opioid receptor antagonists. J Med Chem (1987) 1.35
Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther (1982) 1.35
Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci (2009) 1.34
Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther (1992) 1.32
Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol Sci (1989) 1.27
The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther (2009) 1.27
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem (1988) 1.25
5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur J Pharmacol (2000) 1.23
Pharmacological profiles of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) on the mouse vas deferens preparation. Eur J Pharmacol (1982) 1.21
A single residue, aspartic acid 95, in the delta opioid receptor specifies selective high affinity agonist binding. J Biol Chem (1993) 1.19
Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther (1991) 1.18
Narcotic-antagonist analgesics: interactions with cholinergic systems. J Pharmacol Exp Ther (1969) 1.17
Involvement of phospholipid signal transduction pathways in morphine tolerance in mice. Br J Pharmacol (1999) 1.17
The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur J Pharmacol (1981) 1.16
Morphine amplifies HIV-1 expression in chronically infected promonocytes cocultured with human brain cells. J Neuroimmunol (1994) 1.16
Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J Pharmacol Exp Ther (1982) 1.15
Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. J Pharmacol Exp Ther (1983) 1.15
Antineoplastic activity of cannabinoids. J Natl Cancer Inst (1975) 1.14
Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J Med Chem (1998) 1.14
An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther (2012) 1.13
Optically pure (+)-nicotine from (+/-)-nicotine and biological comparisons with (-)-nicotine. J Med Chem (1979) 1.12
Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J Med Chem (1986) 1.11
Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem (2000) 1.11
Pharmacology of some marijuana constituents and 2 heterocyclic analogues. Nature (1970) 1.11
Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites. J Med Chem (1982) 1.10
Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. Eur J Pharmacol (1984) 1.09
Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther (1991) 1.09
Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J Med Chem (1985) 1.09
Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers. J Med Chem (1986) 1.08
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. J Med Chem (2001) 1.08
Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex. Eur J Pharmacol (1990) 1.06
Stereochemical factors and receptor interactions associated with narcotic analgesics. J Pharm Sci (1966) 1.06
Compounds affecting the central nervous system. 4. 3 Beta-phenyltropane-2-carboxylic esters and analogs. J Med Chem (1973) 1.05
Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J Pharmacol Exp Ther (1999) 1.04
Quantitative studies of the antagonism of morphine by nalorphine and naloxone. J Pharmacol Exp Ther (1969) 1.04
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties. J Med Chem (1979) 1.04
Enkephalin antinociception in mice is mediated by delta 1- and delta 2-opioid receptors in the brain and spinal cord, respectively. Eur J Pharmacol (1993) 1.03
Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. J Med Chem (2001) 1.03
Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Biochem Behav (1998) 1.03
Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine (2012) 1.03
Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine. J Med Chem (1988) 1.02
Opioid agonist and antagonist bivalent ligands as receptor probes. Life Sci (1983) 1.02
Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem (2000) 1.02
Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte-stimulating hormone. J Pharmacol Exp Ther (1984) 1.02
Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J Pharmacol Exp Ther (1981) 1.02
Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor. Neuropharmacology (1999) 1.01
Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance. Br J Pharmacol (2007) 1.00
A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia (1977) 1.00
Safety assessment of allylalkoxybenzene derivatives used as flavouring substances - methyl eugenol and estragole. Food Chem Toxicol (2002) 1.00
Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem (1986) 1.00
Affinity labels for opioid receptors. Annu Rev Pharmacol Toxicol (1985) 1.00
The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl) (1995) 0.99
Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity. Science (1979) 0.98
Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity. J Med Chem (1988) 0.98
Stimulation by corticotropin-releasing factor of the release of immunoreactive dynorphin A from mouse spinal cords in vitro. Eur J Pharmacol (1992) 0.98
The increased efficacy of narcotic antagonists induced by various narcotic analgesics. J Pharmacol Exp Ther (1974) 0.98
Quantitative studies on the antagonism by naloxone of some narcotic and narcotic-antagonist analgesics. Br J Pharmacol (1970) 0.98
Relationship of brain morphine levels to analgesic activity in acutely treated mice and rats and in pellet implanted mice. J Pharmacol Exp Ther (1975) 0.98
A highly selective delta 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur J Pharmacol (1992) 0.97
Involvement of intracellular calcium in morphine tolerance in mice. Pharmacol Biochem Behav (1999) 0.97
Studies on the quantitative antagonism of analgesics by naloxone and diprenorphine. Eur J Pharmacol (1972) 0.97
Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J Pharmacol Exp Ther (1997) 0.97
Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochem Res (1996) 0.97